Exchange: NYSEArca·Updated 07:59 PM EDT
VTI logo

VTIVanguard Total Stock Market ETF

$362.22
$0.7163
(0.20%)
Today
Closed $362.22
$0.65
(0.18%)
After Hours
Vol2.74M
52W High$374.70
52W Low$301.39
News
all
press releases
Could Buying VTI Today Set You Up for Life?
Key PointsThe Vanguard Total Stock Market ETF (VTI) holds many of the same top companies as the S&P 500 but also includes small- and mid-cap stocks...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease.
Stocktwits
News Placeholder
S&P 500, Nasdaq End Week Lower As Investors Rotate Out Of Tech, AI Plays — ON, AAPL, SLS, INFQ, NKE in Focus
The Dow Jones ended its third consecutive week higher amid cooling oil prices and strength in pharma and materials stocks.
Stocktwits
News Placeholder
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle
The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle.
Stocktwits
News Placeholder
UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug
Unicyive Therapeutics is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection.
Stocktwits
News Placeholder
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.
Stocktwits
News Placeholder
AAPL Stock On-Track For Worst Week In Four Months — Mac, iPad Price Hikes Spurs Demand, Margins Debate
Morgan Stanley thinks Apple’s big price hike is seen as "an unprecedented push to protect margins."
Stocktwits
News Placeholder
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe
The European Commission will review the recommendation and is expected to issue a final decision in the coming months.
Stocktwits
News Placeholder
Apple Hiked Prices Of Its Products Due To Soaring Memory Costs — And Dan Ives Says AAPL Can Get Away With It
Wedbush maintained its ‘Outperform’ rating and $400 price target, implying an upside potential of 45% from Thursday’s closing price.
Stocktwits
News Placeholder
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline
Kymera said that it finished enrolling patients nearly six months ahead of schedule in a mid-stage trial for KT-621.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.